-
Posted by
Two Blokes Apr 22 -
Filed in
Stock
-
45 views
HONG KONG, April 21, 2025 /PRNewswire/ -- Venus MedTech (Hangzhou) Inc. (Stock Code: 2500.HK, hereinafter referred to as "Venus Medtech" or the "Company"), a global leader in structural heart therapies, has announced financial results for the year ended December 31, 2024 ("the Year"), demonstrating significant improvements in profitability and operational discipline despite market challenges. Key Financial Highlights Revenue: RMB471 million, with overseas revenue growing 13.53% YoY to RMB82.5 million.
